| MECHANIS MS OF E JACUL ATION

| Central nerve control of ejaculation
Control of ejaculation in the brain is divided into two sites that promote or suppress the nerves in the spinal ejaculation center. According to Giuliano, 1 two sites of the hypothalamus, (1) the paraventricular nucleus (PVN) and (2) the medial preoptic nucleus (MPOA), secrete dopamine and send an ejaculatory promoting signal to the dopamine 2 (D 2) receptor. Alternatively, the periaqueductal gray (PAG) of the midbrain secretes serotonin and sends ejaculation-suppressing signals to the nucleus paragigantocellularis (NPGi) of the pons.
| Peripheral nerve control of ejaculation
The ejaculation mechanism at the level below the spinal cord is described herein (Figure 1 ). The efferent stimulation from the 11th thoracic spinal cord to the 2nd lumbar spinal cord (sympathetic nervous system), which receives the ejaculation-promoting signal from a higher ejaculation center (the brain), is transmitted to the testis, epididymis, vas deferens, seminal vesicles, ejaculatory duct, prostate, and the internal urinary sphincter of the bladder neck via the hypogastric nerve (sympathetic nerve). This results in the emission of semen in the posterior urethra. Also, the efferent stimulation from S2 to S4 (sacral spinal cord, the parasympathetic nervous system), which receives an ejaculation-promoting signal from the brain, is transmitted to the seminal vesicles and the prostate via the pelvic nerve (parasympathetic nerve). This involves the emission of seminal fluid into the posterior urethra via the pelvic nerve. In addition, the afferent stimulation from the penile dorsal nerve is also transmitted to S2-S4 through the pudendal nerve (somatic nervous system) and the efferent signals from S2 to S4 are sent to the bulbocavernosus muscle, the ischiocavernous muscle, and the external urinary sphincter through the pudendal nerve. These muscles contract (external urinary sphincter is relaxed) and eject (expulsion) semen from the external urethral opening.
| Three phases of ejaculation
Ejaculation is expressed in order of next three phases. 3 
| Emission
Emission is the first stage of ejaculation. Semen (a mixture of spermatozoa from the testis, prostatic fluid, and seminal vesicle fluid) is excreted into the prostatic urethra mainly by efferent stimulation from the hypogastric nerve (sympathetic nerve).
| Ejection (Expulsion)
Efferent stimulation from the pudendal nerve (the somatic nerve) causes the periurethral, the bulbocavernosus, and the pelvic floor muscles to rhythmically contract, ejaculating semen from the external urethral meatus. At the moment of ejection, the internal urinary sphincter of the bladder neck is closed so that the semen does not reflux back to the bladder.
| Orgasm
Concurrent with the ejaculation, the posterior urethral pressure increases and the seminal colliculus (verumontanum) stimulates the brain center via the pudendal nerve to create a pleasant sensation (orgasm).
EjD is caused by a failure of any of these ejaculation mechanisms.
F I G U R E 1 Peripheral nerve control of ejaculation. The efferent stimulation from the 10th thoracic spinal cord to the 2nd lumbar spinal cord is transmitted to ejaculatory-related organs via the hypogastric nerve (sympathetic nerve), and emission occurs. Also, the efferent stimulation from S2 to S4 via the pelvic nerve (parasympathetic nerve) causes the emission. The afferent stimulation from the penile dorsal nerve is also transmitted to S2-S4 through the pudendal nerve (somatic nervous system) and the efferent signal from S2 to S4 causes ejection (expulsion) of semen 
| NE W JAPANE S E VER S I ON OF E JD CL A SS IFI C ATI ON FOR CLINI C ALLY E A SY TO US E IN 2 019
The author would like to propose a new EjD classification, based on the 2015 ICSM and 2018 ICD-11 classifications, that has been modified into a form that is easier to use in clinical practice of EjD in Japan (Table 1) .
Based on patient symptoms, this would create two new categories: (a) impossible to ejaculate and (b) abnormal time to ejaculation. a. Impossible to ejaculate When a patient complains of being "unable to ejaculate," this can be classified into the following three disease types: (1) retrograde ejac- 
b. Abnormal time to ejaculation
Two items were proposed: (1) premature ejaculation (PE) and (2) delayed ejaculation (DE). Premature ejaculation is equivalent to HA03.1, but "PE" is more widely used in literature searches and conference presentations worldwide. In addition, DE was limited to someone who, after significant time, eventually ejaculates from the external urethral meatus. The basis of this classification is described below. Figure 2 shows the types of EjD cases seen in our clinic during the past 33 years and EjD cases from the Toho University Reproduction Center dealing with a large number of EjD cases in Japan. It should be noted that in both facilities, "impossible to ejaculate" accounts for the majority of cases (81% and 77% 
| Both ejaculation by masturbation and intravaginal ejaculation are impossible and include two types
| Retrograde ejaculation
This condition arises when semen released in the posterior urethra flows back into the bladder, as diagnosed by 5 or more spermatozoa/ HPF in the urine sediment immediately after masturbation. 7 In recent years, cases with diabetes as the underlying disease are increasing.
| Anejaculation
There are two types of anejaculation: (1) emission less, when the patient is unable to discharge semen into the posterior urethra, and
(2) expulsion less, when the patient is unable to vigorously discharge semen from the external urethral meatus. The cause of anejaculation is often the same as the cause of retrograde ejaculation (eg, diabetes and spinal cord injury), but can also be caused by drug side effects (psychotropic drugs and alpha-adrenergic blockade agent for prostate hypertrophy treatment 8 ; 
| Intravaginal ejaculatory dysfunction (IVEjD)
While ejaculation by masturbation can occur in IVEjD, it is not possible during sexual intercourse. There are two types of IVEjD, those with and without ED. In the reproductive age-group, this problem becomes more serious because IVEjD can cause male infertility. No term corresponding to IVEjD can be found in Western literature. In the ICD-11 classification, it is probably considered to be a pathological condition included in HA03.2. In Japan, there are a large number of IVEjD patients who visit clinics for the treatment of sexual dysfunction and male infertility. 11 Therefore, IVEjD is classified and described separately in this newly proposed classification of EjD in 2019.
| IVEjD with ED
In this type of IVEjD, one cannot maintain an erection (a symptom of ED); therefore, it is not possible to ejaculate in the vagina.
F I G U R E 2 In both facilities, "impossible to ejaculate and IVEJD" accounts for the majority of cases (81% and 77%) TA B L E 2 Drugs that can cause anejaculation or delayed ejaculation (modified c Gripping the penis too strongly during masturbation. According to Abe, people who masturbate with a grip of 10 kg or more will have difficulty in intravaginal ejaculation. 
| Delayed ejaculation (DE)
Ejaculation is possible, but with an IELT of 25-30 minutes or more.
The causes are often psychogenic, but there are some cases of organic diseases that cause anejaculation (diabetes and drug side effects, etc). In classifications of ICSM in 2015 and ICD-11, IVEjD is included in DE, but in the new classification, only DE in a narrow sense is defined and IVEjD is excluded.
| Pain during ejaculation (painful ejaculation)
Pain in the genital or pelvic region, headache, etc, appears during or immediately after ejaculation or orgasm. Prostatic diseases such as prostatitis and prostatic hyperplasia are often the underlying diseases, but there are cases where the cause is unknown.
| Anhedonic ejaculation (non-enjoyable ejaculation, spontaneous ejaculation)
Ejaculation without sexual pleasure: Most are psychogenic.
In the 2015 ICSM classification, anorgasmia is included in the category of EjD, but in clinical practice, EjD and orgasm disorders often experience separate complaints. For this reason, anorgasmia is not included in the new EjD classification.
| D IAG NOS IS OF E JD
Diagnosis of EjD is basically possible by conducting interviews.
Patients who visit male sexual dysfunction clinics often complain of "ED" even in cases of EjD; therefore, it is important to distinguish between the two.
Since EjD is divided into many types with diverse causes, "to do list" (Figure 3 13 ) was created to help with this diagnosis. In particular, because anejaculation or DE is sometimes caused by the side effects of drugs, an accurate identification of the medication contents is required.
With respect to the questionnaire on EjD, question no. 9 of the validated Japanese version of the International Index Erectile Function (IIEF) is associated with ejaculation. 14 
| TRE ATMENT OF E JD
When treating EjD, it is important to first clarify which patients have priority. This is especially important in the reproductive age-group since there are many cases where patients want to raise children. In this group, the age of the partner is also an important factor in selecting a treatment method. Treatment of EjD can be roughly divided into pharmacotherapy (Table 3 ) and nonpharmacotherapy (behavior therapy, reproductive therapy, etc).
Unfortunately, it is important to note that all pharmacotherapies are for off-label use in Japan.
| Treatment of PE
| Selective serotonin reuptake inhibitor (SSRI)
Selective serotonin reuptake inhibitor is currently the first-line treatment for PE. 18 Serotonin (5-hydroxytryptamine: 5-HT) is a neurotransmitter involved in emotions, but has an inhibitory effect on ejaculations.
Serotonin released from presynaptic neurons acts on serotonin receptors in postsynaptic neurons, but is recovered by the serotonin transporter (reuptake). Selective serotonin reuptake inhibitor inhibits the serotonin transporter and inhibits serotonin reuptake, and as a result, the serotonin concentration is maintained at a high level, which suppresses ejaculation. Goodman, for the first time in 1977, reported that clomipramine hydrochloride (Anafranil ® ), an antidepressant that has non-selective serotonin uptake inhibitory activity, was effective for PE. 19 Then in the 1990s, SSRIs were 
| Topical anesthetics as penile application
Topical anesthetics as penile application are used for the treatment of PE by lowering the penile perception threshold. In 1943, Schapiro 23 applied an anesthetic ointment onto the penis of patients with PE for the first time. The efficacy and safety of this treatment have been confirmed. 24 We apply it on the glans and shafts of penises before sexual intercourse. If not wiped off just before sexual intercourse, it will be absorbed in the vagina and will Lidocaine jelly is available in Japan.
| Other drugs
The efficacy of PDE5 inhibitors, 28 tramadol, 29 and α-adrenergic blockers (such as silodosin) 30 against PE has been reported. However, tramadol is not the first drug of choice due to side effect concerns of addiction and difficulty in breathing. In addition, PDE5 inhibitors have been recommended to be used in combination with SSRIs. 31
| Behavioral therapy (a) Stop and Start method
This is a behavioral therapy for PE proposed by Semans 32 in 1956.
It is a method to increase the ejaculation threshold and to treat PE.
The original method began with penis stimulation by a partner, but I 
(c) Problems of behavioral therapy
Although behavioral therapies have an efficacy of 90% or more in the short term, there are problems with the persistence of their effects and limitations as PE therapy have also been pointed out. 35 Also, understanding and cooperation of the partner is essential with consideration for the partner's frustration level. 36
| Brief PE treatment summary
1. Primary PE is mainly treated with pharmacotherapy.
2. Secondary PE and situational PE are treated by behavioral therapy or pharmacotherapy, or combination of both therapies depending on the wishes of the patient and partner. 18
| Treatment of retrograde ejaculation (RE)
In the treatment of RE, it is important to first ask the patient "Would you like to have a baby?" For those who do not wish to have a baby (mainly middle-aged or older), if an accurate diagnosis is made and understood, only follow-ups without treatment may be sufficient.
On the other hand, patients in the reproductive age group who would like to have a baby will receive the pharmacotherapy described below, and in the case of ineffective cases of pharmacotherapy, urinary sperm retrieval will be performed. Aggressive treatment of RE is especially necessary for young patients in the reproductive age group who have a strong desire for raising children, but have diabetes, spinal cord injuries, or retroperitoneal lymph node dissections after testicular tumors. The tricyclic antidepressants have a sympathetic receptorstimulating action by inhibiting the serotonin and noradrenaline transporters (amine transporter) and consequently inhibiting the reuptake of adrenaline. Therefore, the bladder neck is contracted so that intravesical reflux of the sperm is blocked.
| Pharmacotherapy of RE
However, since tricyclic antidepressants also have an inhibitory action of acetylcholine (muscarinic) receptors at the postsynaptic level, they have side effects such as feeling thirsty, constipation, and dysuria. In addition, inhibitory effects on histamine H1 receptors have the disadvantage of having side effects such as sleepiness.
Overseas, daily administration of the first-generation tricyclic antidepressant imipramine (Tofranil ® ) 75-225 mg/d is recommended. 18, 37 In Japan, Koga et al 38 been reported as successful cases for partner's pregnancy and delivery including our own case. [39] [40] [41] [42] Among successful cases, 7 people (58%) had diabetes mellitus (DM); therefore, for RE cases associated with DM who desire children, amoxapine is considered to be the first-choice drug. In Japan, in 2018 off-label use of amoxapine for RE was approved in the medical fee review. 43
| Urinary sperm retrieval for RE
Sperm ejected into the bladder is collected and subjected to assisted reproductive technology (ART) such as intrauterine insemination | 339 OTANI (IUI), in vitro fertilization, and micro-insemination. In patients with RE who desire raising a child, urinary sperm retrieval is indicated when pharmacotherapy is ineffective. Among the recovery methods, the Hotchkiss method reported by Hotchkiss et al 44 in 1955 is most the notable: (1) limit water intake 6 hours before the operation to reduce urine volume (to reduce contact between urine and sperm);
(2) empty the bladder by withdrawing urine and perform bladder lav- 
| Treatment of anejaculation
As mentioned in (4.1.2.), there are two types of anejaculation: emission less and expulsion less, but these two types are clinically difficult to distinguish. For this reason, this literature explains the treatment of emission less.
Patients who do not hope to have children can be divided roughly into 3 groups: (1) "psychological" complaints about anejaculation, 45 (2) patients who want to know the cause of anejaculation or worry about the adverse effects to their bodies, or (3) compensation issues (medical lawsuits, workers' compensation, traffic accidents, etc). In groups 2 and 3, there are many cases where only diagnosis and no treatment are required, with only group 1 being targeted for pharmacotherapy. On the other hand, for patients who wish to raise children, the situation is serious. If time is available, pharmacotherapy can be provided for a while, but usually semen is collected by artificial ejaculation and proceeds to ART. Additionally, endocrinological abnormalities (hypogonadotropic hypogonadism, pituitary tumor, etc), ejaculatory duct obstructions, or drug side effects are all considered in the treatment regimen. In the case of emission less due to the side effect of the drug, the drug is discontinued if possible.
| Pharmacotherapy of emission less
The following drugs that act to increase ejaculation-promoting substances are considered effective in treating emission less. Some drugs can overlap with the pharmacotherapy of RE. All drugs are off-label in Japan.
1. Dopamine receptor agonists: amantadine (Symmetrel ® ), apomorphine, cabergoline (Cabaser ® ), etc, promote ejaculation by increasing the amount of dopamine.
Noradrenaline-dopamine reuptake inhibitory action: Bupropion
promotes ejaculation by increasing dopamine and noradrenaline.
3. Sympathetic α1 receptor agonists: ephedrine (Ephedrin "NAGAI" ® ), pseudoephedrine, midodrine (Metligine ® ), etc Ejaculation is promoted by noradrenaline increase.
Noradrenaline reuptake inhibitory action by amine transporter
inhibition: tricyclic antidepressants: imipramine (Tofranil ® ), amoxapine (Amoxan ® ), etc Ejaculation is promoted by noradrenaline increase.
Noradrenaline reuptake inhibitory action with sympathetic α2
receptor antagonist: yohimbine, etc. Ejaculation is promoted by noradrenaline increase.
6. Serotonin antagonist: cyproheptadine (Periactin ® ) and yohimbine.
Ejaculation is promoted by reducing the amount of serotonin, which is an ejaculation inhibitor.
Oxytocin:
Oxytocin is an ejaculatory agent. 
| Penile Vibratory Stimulation (PVS) for the treatment of emission less
| Electroejaculation (EE) for the treatment of emission less
Electroejaculation is a treatment for emission less by transrectal electrostimulating the prostate and seminal vesicles to induce ejaculation. The mechanism of EE causes seminal emission and bladder neck closure by electrically stimulating sympathetic postganglionic fibers and emission-related organs innervated by the sympathetic nervous system, thereby antegrade ejaculation occurs. In the veterinary field, this has been clinically applied for breeding purposes since 1936. 49 
| ART (testicular sperm extraction [TESE] and intracytoplasmic sperm injection [ICSI])
For anejaculation cases who hope for a child, ART (TESE and ICSI) should be simultaneously performed with other treatments not to waste time to have a baby.
| Treatment options for patients rendered emission less due to pharmacologic drug side effects
If possible, the discontinuation or withdrawal of the causative drug is desirable, but confirmation by the prescribing physician is essential.
| Treatment options for the patient rendered emission less by a rare case of male hypogonadotropic hypogonadism (MHH) or a distal ejaculatory duct obstruction
HCG-FSH therapy for a patient with MHH and a transurethral resection (TUR) operation in the distal ejaculatory duct obstruction are indicated.
| 341 OTANI 6.4 | Treatment of Intravaginal ejaculatory dysfunction (IVEjD)
| Treatment of IVEjD with ED
In this type, the treatment of ED is preceded.
| Treatment of IVEjD without ED
Behavioral therapy (a) Guidance of appropriate masturbatory techniques:
Many cases of IVEjD have problems because of dysfunctional masturbatory methods learned in adolescence. For this reason, the patient must be re-taught masturbatory techniques using a softer grip of the penis with the hand and using thrusting motions. According to Abe, 12 if it is difficult to masturbate with bare hands, begin masturbating with sheets or gauze first, or use condoms, and gradually shift to bare-handed masturbation. In some cases, training methods for masturbation in a simulated intravaginal environment provided by the TENGA ® masturbatory aid are recommended. 63 It has also been proposed that adolescent sex education should include education on how to do proper masturbation to prevent iIVEjD. [64] [65] [66] [67] (b) Pharmacotherapy of IVEjD in addition to behavioral therapy
As an adjunct treatment to masturbation training, there are also cases of effective treatment with oral administration of yohimbine (a sympathetic α-2 receptor antagonist) 1 hour before sexual intercourse. 68 (c) Sexual intercourse by partner-astride position
If the masturbatory guidance is not successful, a method of performing masturbation in the supine position and then inserting the penis into the vagina with the partner in the astride position right before ejaculation, is recommended. The partner's understanding and cooperation often result in a successful conception.
Assisted reproductive technology (ART) for patients with IVEjD
Assisted reproductive technology, with intrauterine insemination (IUI) or intravaginal insemination (IVI), should be simultaneously performed with behavioral therapy or pharmacotherapy not to waste time to have a baby. The author has experienced IVEjD cases whose intravaginal ejaculation became possible after raising a child conceived by IUI.
| Treatment of delated ejaculation (DE)
Basically, use the same drug as the pharmacotherapy for emission less treatment.
| Treatment of painful ejaculation
Since prostate disease such as prostatitis and prostatic hypertrophy is often underlying diseases, priority is given to analgesics.
| Treatment of spontaneous ejaculation (anhedonic ejaculation)
Sato 69 reported a case of spontaneous ejaculation where oral silodosin was effective.
| CON CLUS ION
In male sexual dysfunction clinics, we begin by distinguishing ED and
EjD. In addition, EjD has more complicated pathological conditions compared with ED and there are many cases with psychogenic factors. Pharmacotherapy and behavioral therapy may be performed according to the patients' wishes. Furthermore, in cases where the problem of male infertility is severe, more invasive treatments may be necessary. In addition, there are many cases PE and IVEjD cases where adolescent masturbation practices have caused problems.
I would like to conclude this paper hoping for the emergence of a new breakthrough treatment for EjD.
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